Seaport Therapeutics, Inc. (SPTX) Stock Statistics & Valuation Metrics

Seaport Therapeutics, Inc. has a market cap or net worth of $1.16B. The enterprise value is $0.00.

Seaport Therapeutics, Inc. has 53,530,550 shares outstanding. The number of shares has decreased by -2.65% in one year.

Seaport Therapeutics, Inc.’s return on equity (ROE) is 0.81 and return on invested capital (ROIC) is -36.70%.

The current PE Ratio of Seaport Therapeutics, Inc. is ―. Seaport Therapeutics, Inc.’s PEG ratio is 0.00.

In the last 12 months, Seaport Therapeutics, Inc. had revenue of 0.00 and earned -74.88M in profits. Earnings per share was -1.94.

In the last 12 months, operating cash flow was -20.17M and capital expenditures 0.00, giving a free cash flow of -20.17M billion.

Seaport Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Seaport Therapeutics, Inc. upcoming earnings date is Jun 8, 2026, Before Open (Confirmed).

Seaport Therapeutics, Inc. as a current ratio of 17.46, with Debt / Equity ratio of -5.49%

In the past 12 months, Seaport Therapeutics, Inc. has paid 773.00K in taxes.

Seaport Therapeutics, Inc. EV to EBITDA ratio is -8.45, with an EV/FCF ratio of -9.27.

Seaport Therapeutics, Inc. has $182.60M in cash and marketable securities with $5.34M in debt, giving a net cash position of $177.26M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Seaport Therapeutics, Inc. is $35.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy